Rebekah Lewis
Family · Sahuarita, AZNPI 1386987717
Payments from drug & device makers
Across 90 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$596
- Sunovion Pharmaceuticals Inc.$134
- AstraZeneca$107
- Amgen$85
- Boehringer Ingelheim$82
- AbbVie$81
- plus $447 from 16 others
What the payments were for
- Food & beverage$1,533100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 38 | $596 |
| Sunovion Pharmaceuticals Inc. | 6 | $134 |
| AstraZeneca | 7 | $107 |
| Amgen | 5 | $85 |
| Boehringer Ingelheim | 4 | $82 |
| AbbVie | 4 | $81 |
| Novo Nordisk | 5 | $75 |
| Pfizer | 3 | $57 |
| Currax Pharmaceuticals LLC | 4 | $55 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Bioventus LLC | 1 | $24 |
| Zimmer Biomet | 1 | $21 |
| Lundbeck LLC | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $18 |
| Globus Medical | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Smith+Nephew | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$1,533 in reported general payments places this provider in the 75th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $69,274 |
| EliquisApixaban | 49 | $51,163 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $37,791 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $17,711 |
| RybelsusSemaglutide | 12 | $10,845 |
| XareltoRivaroxaban | 12 | $7,980 |
| OxycontinOxycodone Hcl | 12 | $7,042 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $5,210 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 140 | $3,357 |
| Levothyroxine Sodium | 265 | $3,319 |
| Morphine Sulfate ErMorphine Sulfate | 71 | $3,066 |
| Gabapentin | 111 | $3,049 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 107 | $2,514 |
| Duloxetine Hcl | 74 | $2,334 |
| Atorvastatin Calcium | 168 | $2,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $75 | $80,11863 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $596 | $55,50248 claims |
| PfizerEliquis | $57 | $51,16349 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,119 family providers in Arizona.
Other family in Sahuarita
- Sharon MagalonaMesa$449K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Susan SarabiaSun City West$114K
- Lindsay CarterTucson$108K
- Audrey StevensonPhoenix$83K
- Keith MorsePrescott$83K
- Celeste FineGilbert$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.